PL408169A1 - Zastosowanie porfiryn kobaltu - Google Patents

Zastosowanie porfiryn kobaltu

Info

Publication number
PL408169A1
PL408169A1 PL408169A PL40816914A PL408169A1 PL 408169 A1 PL408169 A1 PL 408169A1 PL 408169 A PL408169 A PL 408169A PL 40816914 A PL40816914 A PL 40816914A PL 408169 A1 PL408169 A1 PL 408169A1
Authority
PL
Poland
Prior art keywords
treatment
peripheral blood
application
neutropenia
agent
Prior art date
Application number
PL408169A
Other languages
English (en)
Other versions
PL233504B1 (pl
Inventor
Agata Szade
Krzysztof Szade
Alicja Józkowicz
Józef Dulak
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL40816914A priority Critical patent/PL233504B1/pl
Priority to EP15727081.0A priority patent/EP3139917B1/en
Priority to PCT/PL2015/050014 priority patent/WO2015171001A1/en
Priority to US15/309,485 priority patent/US10010557B2/en
Publication of PL408169A1 publication Critical patent/PL408169A1/pl
Priority to US16/018,229 priority patent/US10328085B2/en
Publication of PL233504B1 publication Critical patent/PL233504B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie porfiryny kobaltu do wytwarzania środka do mobilizacji komórek ze szpiku kostnego do krwi obwodowej, korzystnie środka stosowanego w leczeniu neutropenii wrodzonych, w leczeniu oraz profilaktyce neutropenii spowodowanych chemioterapią, radioterapią oraz indukowanych farmakologicznie, w leczeniu ostrej białaczki szpikowej, ostrej białaczki limfocytarnej, zespołów mielodysplastycznych oraz w celu zwiększania ilości krążących we krwi obwodowej hematopoetycznych komórek macierzystych, w celu późniejszej ich izolacji w procesie aferezy i przeszczepiania allogenicznego lub autologicznego.
PL40816914A 2014-05-09 2014-05-09 Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek PL233504B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL40816914A PL233504B1 (pl) 2014-05-09 2014-05-09 Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek
EP15727081.0A EP3139917B1 (en) 2014-05-09 2015-05-09 Cobalt protorphyrin ix for the treatment of blood-related disorders
PCT/PL2015/050014 WO2015171001A1 (en) 2014-05-09 2015-05-09 Cobalt porphyrins for the treatment of blood-related disorders
US15/309,485 US10010557B2 (en) 2014-05-09 2015-05-09 Cobalt porphyrins for the treatment of blood-related disorders
US16/018,229 US10328085B2 (en) 2014-05-09 2018-06-26 Cobalt porphyrins for the treatment of blood-related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL40816914A PL233504B1 (pl) 2014-05-09 2014-05-09 Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek

Publications (2)

Publication Number Publication Date
PL408169A1 true PL408169A1 (pl) 2015-11-23
PL233504B1 PL233504B1 (pl) 2019-10-31

Family

ID=53284481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL40816914A PL233504B1 (pl) 2014-05-09 2014-05-09 Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek

Country Status (4)

Country Link
US (1) US10010557B2 (pl)
EP (1) EP3139917B1 (pl)
PL (1) PL233504B1 (pl)
WO (1) WO2015171001A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501219A (ja) * 1986-02-21 1988-05-12 ザ ロツクフエラ− ユニバ−シテイ 内分泌系ホルモン生成抑制用非経口投与治療組成物および方法
US5192757A (en) 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
US5149697A (en) 1991-04-18 1992-09-22 Glaxo Inc. Cobalt porphyrin pharmaceutical compositions
US5776966A (en) 1992-05-27 1998-07-07 University Of British Columbia Selective cell inactivation in blood
WO2005084665A1 (ja) 2004-03-04 2005-09-15 Makoto Yuasa 金属ポルフィリン錯体包埋ニオソーム、その製造法およびこれを利用する医薬
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
US20170196882A1 (en) 2017-07-13
EP3139917B1 (en) 2019-07-03
WO2015171001A1 (en) 2015-11-12
US10010557B2 (en) 2018-07-03
PL233504B1 (pl) 2019-10-31
EP3139917A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
PH12020550216A1 (en) Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
EA201992155A1 (ru) Способы криогенного хранения
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
PE20160167A1 (es) Composiciones y metodos para alterar la senalizacion del segundo mensajero
CL2016001055A1 (es) Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras.
CY1120201T1 (el) Ενωσεις, συνθεσεις και μεθοδοι με χρηση ανταγωνιστων σελεκτινης ε για κινητοποιηση αιμοποιητικων κυτταρων
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
CL2015002640A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
MX393494B (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
ECSP14000357A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
EA201592203A1 (ru) Способы лечения таупатии
CL2015002620A1 (es) Derivados piridin-4-ilo
MX2018009408A (es) Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof